Drugs / Aiparolitoworixureli
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07068763 | Oct 2025 → Dec 2026 expected | rectal cancer | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aiparolitoworixureli | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07068763 ↗ |
| Action | Inhibit | “PD-1/CTLA-4 inhibitor” NCT07068763 ↗ |
| Modality | Monoclonal antibody | “Intravenous PD-1/CTLA-4 bispecific monoclonal antibody” NCT07068763 ↗ |
| Route | Intravenous | “Intravenous PD-1/CTLA-4 bispecific monoclonal antibody at 5 mg/kg every 3 weeks for four cycles, starting on Day 8 after completion of radiotherapy.” NCT07068763 ↗ |